ContraFect Corporation Names Steven C. Gilman, PhD Chief Executive Officer

ContraFect Corporation(CFRX) (CFRXW) (“ContraFect,” “we,” or the “Company”), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for lifethreatening, drugresistant infectious diseases, today announced that it has named Steven C. Gilman, PhD, as Chief Executive Officer of ContraFect, effective immediately. Dr. Gilman has served as Interim Chief Executive Officer since March 21, 2016. He will continue to serve as Chairman of the Board of Directors of the Company.

This entry was posted in Recent Development News: Q3 - 2016, Recent Developments. Bookmark the permalink.
Read Full Article »